ARTICLE | Company News
Keryx sales and marketing update
August 8, 2016 7:00 AM UTC
Keryx said it expects an “imminent” interruption in the supply of Auryxia ferric citrate that will disrupt patient access to the drug. The company attributed the interruption to a “production-related issue” as its contract manufacturer converts Auryxia’s API to finished drug product. Keryx expects to make Auryxia available again next quarter, when the drug supply is back to adequate levels. Keryx markets Auryxia in the U.S. to control serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. It is approved in the EU as Fexeric to treat hyperphosphatemia in adult CKD patients. The therapy is an oral ferric iron-based phosphate binder. ...